The following SNPs showed a nominally statistically significant interaction with acrylamide intake for both endometrial and ovarian cancer, with the same genotypes showing the strongest positive association between acrylamide and cancer risk in never-smokers: rs11252859 in AKR1C1, rs3448 in GPX1, and rs1800566 in NQO1. Additionally, there were clear differences in the acrylamide dose–response between the same genotypes for both cancers for: rs1280350 in MGC1295 (among never-smokers), and rs6428830 in the HSD3B1/B2 gene cluster (particularly among never-smokers). This evidence concerns the gene GPX1 and cancer.